These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17484896)

  • 61. Metabolism and antiviral activity of ribavirin.
    Parker WB
    Virus Res; 2005 Feb; 107(2):165-71. PubMed ID: 15649562
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Reply to Harrington et al.
    Sidharthan S; Kohli A; Kottilil S
    Clin Infect Dis; 2015 Aug; 61(4):667-8. PubMed ID: 26002847
    [No Abstract]   [Full Text] [Related]  

  • 63. Plugging the holes in hepatitis C virus antiviral therapy.
    Griffin SD
    Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12567-8. PubMed ID: 19666619
    [No Abstract]   [Full Text] [Related]  

  • 64. In vitro and in vivo studies of ribavirin action on Brazilian Orthobunyavirus.
    Livonesi MC; De Sousa RL; Badra SJ; Figueiredo LT
    Am J Trop Med Hyg; 2006 Nov; 75(5):1011-6. PubMed ID: 17124004
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Photolabeling probes of ribavirin and EICAR.
    Wu Q; Qu F; Wan J; Xia Y; Peng L
    Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):999-1008. PubMed ID: 16248080
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Adverse events raise concerns over safety of new hepatitis C drugs.
    McCarthy M
    BMJ; 2017 Jan; 356():j490. PubMed ID: 28137772
    [No Abstract]   [Full Text] [Related]  

  • 67. ENT1 and treatment of viral diseases.
    Panigrahi R; Dash S
    Oncotarget; 2015 Oct; 6(32):32281-2. PubMed ID: 26431496
    [No Abstract]   [Full Text] [Related]  

  • 68. Hepatitis C virus - the Pakistani perspective.
    Jafri SM
    J Coll Physicians Surg Pak; 2003 Aug; 13(8):431-2. PubMed ID: 12921676
    [No Abstract]   [Full Text] [Related]  

  • 69. Hepatocyte proliferation and hepatitis C virus kinetics during treatment.
    Dahari H; Rong L; Layden TJ; Cotler SJ
    Clin Pharmacol Ther; 2011 Mar; 89(3):353-4. PubMed ID: 21270791
    [No Abstract]   [Full Text] [Related]  

  • 70. [Occludin, an additional key for hepatitis C virus entry].
    Tews BA; Cocquerel L
    Med Sci (Paris); 2009; 25(6-7):549-51. PubMed ID: 19602343
    [No Abstract]   [Full Text] [Related]  

  • 71. Can we use viral kinetic models to individualize treatment?
    Guedj J; Nguyen TH
    Liver Int; 2015 Feb; 35(2):297-8. PubMed ID: 25394573
    [No Abstract]   [Full Text] [Related]  

  • 72. [Research on hepatitis C is importance in China].
    Wang YM
    Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):106-7. PubMed ID: 14980117
    [No Abstract]   [Full Text] [Related]  

  • 73. First-phase parameters in hepatitis C viral kinetics.
    Zeuzem S; Herrmann E
    J Viral Hepat; 2002 Sep; 9(5):332-3. PubMed ID: 12225326
    [No Abstract]   [Full Text] [Related]  

  • 74. [Genome-wide association study and clinical application].
    Sugiyama M; Mizokami M
    Nihon Rinsho; 2011 May; 69 Suppl 4():80-5. PubMed ID: 22096898
    [No Abstract]   [Full Text] [Related]  

  • 75. Colombian experience in the management of hepatitis C.
    Gomez-Aldana AJ; Tapias M; Rosselli D
    Liver Int; 2020 Dec; 40(12):3143. PubMed ID: 32602224
    [No Abstract]   [Full Text] [Related]  

  • 76. Strategies for hepatitis C virus treatment failure.
    Huang SC; Kao JH
    J Formos Med Assoc; 2022 May; 121(5):876-878. PubMed ID: 34538553
    [No Abstract]   [Full Text] [Related]  

  • 77. [N,NL-MALONYL-BIS-ETHYLENIMINE AND ITS VARIOUS BIOLOGICAL PROPERTIES].
    BORISOV LB; BEILIN VG; DASHKEVICH LB; IAKOVLEVA GS
    Biull Eksp Biol Med; 1963 Jun; 55():76-9. PubMed ID: 14070884
    [No Abstract]   [Full Text] [Related]  

  • 78. Reply to: "EASL recommendations on treatment of hepatitis C: Final update of the series - some issues".
    EASL Recommendations on Treatment of Hepatitis C Panel. Electronic address: easloffice@easloffice.eu
    J Hepatol; 2021 Feb; 74(2):474-475. PubMed ID: 33229012
    [No Abstract]   [Full Text] [Related]  

  • 79. Targeted prospective hepatitis C virus "lookback" program: is it an efficient and effective use of resources?
    Seheult JN; Triulzi DJ; Kaplan A
    Transfusion; 2018 Aug; 58(8):2084-2085. PubMed ID: 30198611
    [No Abstract]   [Full Text] [Related]  

  • 80. Now Is the Time to Quickly Eliminate Barriers Along the Hepatitis C Cascade of Care.
    Cooper CL
    J Infect Dis; 2018 May; 217(12):1858-1860. PubMed ID: 29534217
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.